MindMed | Investor Presentation Deck | 32 slides

MindMed · 2023-08
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

32
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
Includes chemical structures for drug candidates.summarize
Open slide detailLoop · Golden Circle
04
Uses a visual icon array to represent the '1 in 4' statistic.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
05
The slide uses a Gantt-style chart to show the progress of various drug candidates through clinical development stages.plan_implementation
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
06
The slide uses a circular process diagram for the strategy and a horizontal bar chart to visualize the extension of market protection.present_framework
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
07
plan_implementation
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
08
Uses a brain diagram to visually link specific therapeutic areas to clinical evidence points.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
Uses scientific visualization to illustrate the drug's effect on brain states.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
The slide uses a process diagram to illustrate the biological mechanism of action.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
Uses a nested circle diagram to visualize the funnel of patients from total prevalence to treatment-resistant cases.frame_problem
Open slide detailBeat · AgitateLoop · Cost Of Inaction
12
The slide uses a table to establish clinical credibility by citing historical and modern research.cite_precedent
13
The slide presents clinical trial data (STAI-G scores) showing significant reduction in anxiety symptoms for the LSD group compared to placebo over 24 weeks.show_traction
14
The slide uses a timeline-based clinical trial design diagram.plan_implementation
15
The slide uses a linear process framework to describe the clinical care delivery model.present_framework
Open slide detailBeat · Business Model
16
The slide uses a timeline framework to map specific digital product categories to stages of drug development.plan_implementation
Open slide detailBeat · Business Model
17
The slide uses a process-oriented table structure to outline the commercialization strategy.plan_implementation
Open slide detailBeat · Business Model
18
present_solution
19
The slide uses a timeline-based clinical trial design framework.plan_implementation
20
plan_implementation
21
The slide uses a biological process diagram to illustrate the drug's mechanism of action at the synaptic and neural level.present_solution
22
The chart compares 'Most desired treatment benefits' (dark blue) with 'Aspects of life most impacted by ASD' (light blue).frame_problem
23
The chart compares Social Interaction vs Locomotor Activity across R, R/S, and S variants.present_solution
24
The chart shows a clear performance gap between placebo and MDMA, supporting the therapeutic potential of the drug.show_traction
25
transition
26
present_solution
27
The slide highlights a specific R&D partnership and its downstream strategic value.establish_context
28
The slide features 7 leadership profiles, each with a headshot, name, title, and a column of relevant company logos.other
29
The slide highlights the team's experience through a grid of headshots and a logo-grid of past/current affiliations.other
30
The slide uses a logo-grid to establish credibility through past professional achievements.cite_precedent
31
The slide uses a bulleted list to highlight key company strengths and specific clinical trial statuses for MM-120 and MM-402.summarize